BR112016027773A2 - peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica - Google Patents

peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica

Info

Publication number
BR112016027773A2
BR112016027773A2 BR112016027773A BR112016027773A BR112016027773A2 BR 112016027773 A2 BR112016027773 A2 BR 112016027773A2 BR 112016027773 A BR112016027773 A BR 112016027773A BR 112016027773 A BR112016027773 A BR 112016027773A BR 112016027773 A2 BR112016027773 A2 BR 112016027773A2
Authority
BR
Brazil
Prior art keywords
penetrating
botulinum toxin
cell
protein
recombinant
Prior art date
Application number
BR112016027773A
Other languages
English (en)
Other versions
BR112016027773B1 (pt
Inventor
Kyu Lee Byung
Park Honggyu
Jin Lee Kang
Kim Minjoong
Original Assignee
Atgc Co Ltd
Procell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atgc Co Ltd, Procell Therapeutics Inc filed Critical Atgc Co Ltd
Publication of BR112016027773A2 publication Critical patent/BR112016027773A2/pt
Publication of BR112016027773B1 publication Critical patent/BR112016027773B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Birds (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

a presente invenção refere-se a: um novo peptídeo célula-penetrante; uma composição de proteína recombinante célula-penetrante de toxina botulínica na qual o peptídeo célula-penetrante e a cadeia leve de uma toxina botulínica são fundidos; e um uso da mesma e, mais especificamente, a uma composição que permite a libertação transdérmica de uma proteína recombinante célula-penetrante de toxina botulínica e capaz de ser utilizada localmente para vários tratamentos da pele e fins cosméticos. a proteína recombinante célula-penetrante de toxina botulínica-peptídica da presente invenção pode ser administrada transdermicamente, tendo assim o efeito intrínseco de uma toxina botulínica e simultaneamente tendo maior conveniência de utilização, e assim poder ser aplicada eficazmente como um agonista local para o tratamento de várias doenças e fins estéticos e/ou cosméticos.
BR112016027773-2A 2014-05-29 2015-05-29 Proteína recombinante célula-penetrante de toxina botulínica,composição farmacêutica, composição para um agente dérmico externo e composição cosmética BR112016027773B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004426P 2014-05-29 2014-05-29
US62/004,426 2014-05-29
PCT/KR2015/005434 WO2015183044A1 (ko) 2014-05-29 2015-05-29 신규한 세포투과성 펩타이드 및 이와 보툴리눔 독소 결합체 및 이들의 용도

Publications (2)

Publication Number Publication Date
BR112016027773A2 true BR112016027773A2 (pt) 2017-10-31
BR112016027773B1 BR112016027773B1 (pt) 2023-12-26

Family

ID=54699302

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016027773-2A BR112016027773B1 (pt) 2014-05-29 2015-05-29 Proteína recombinante célula-penetrante de toxina botulínica,composição farmacêutica, composição para um agente dérmico externo e composição cosmética

Country Status (9)

Country Link
US (1) US10300118B2 (pt)
EP (1) EP3156412B1 (pt)
JP (1) JP6243577B2 (pt)
KR (1) KR101882461B1 (pt)
CN (1) CN106459155B (pt)
BR (1) BR112016027773B1 (pt)
CA (1) CA2949653C (pt)
RU (1) RU2670135C2 (pt)
WO (1) WO2015183044A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015183044A1 (ko) * 2014-05-29 2015-12-03 주식회사 프로셀테라퓨틱스 신규한 세포투과성 펩타이드 및 이와 보툴리눔 독소 결합체 및 이들의 용도
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
KR20180114891A (ko) 2016-03-02 2018-10-19 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소를 포함하는 조성물
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
KR101636846B1 (ko) * 2016-06-08 2016-07-07 (주)넥스젠바이오텍 피부 세포 증식 및 항산화 효과가 증가한 보툴리눔 톡신-인간상피세포성장인자 융합단백질 및 이를 유효성분으로 함유하는 피부 재생 및 주름 개선용 화장료 조성물
CN106117352B (zh) * 2016-07-05 2020-10-09 中国人民解放军军事医学科学院军事兽医研究所 抗A型肉毒毒素的人源单链抗体E3-scFv及其应用
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
US20190000935A1 (en) * 2017-06-30 2019-01-03 Allergan, Inc. Dissolving film for delivery of an active agent
ES2930237T3 (es) 2017-07-06 2022-12-09 Merz Pharma Gmbh & Co Kgaa Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos
CN110944677B (zh) * 2017-07-21 2023-02-17 上海科技大学 局部组合物及用途
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
JP7113918B2 (ja) 2018-06-14 2022-08-05 アヴィックスジェン・インコーポレイテッド 細胞透過ペプチドと結合した融合タンパク質、および融合タンパク質または細胞透過ペプチドと上皮細胞成長因子を有効成分として含む組成物
EP3808842A4 (en) * 2018-06-14 2022-11-23 Avixgen Inc. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SEVERE COMPLEX IMMUNE DEFICIENCY WITH A CELL-PERFORMING PEPTIDE AND ADENOSINDEAMINASE FUSION PROTEIN
KR101968873B1 (ko) * 2018-09-21 2019-04-29 아이큐어 주식회사 세포 침투 효과가 우수한 보툴리늄 유래 펩타이드를 포함하는 화장료 조성물
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
JP7262105B2 (ja) 2019-03-29 2023-04-21 国立研究開発法人理化学研究所 細胞透過性配列を有するポリペプチド及びそれを含む組成物
WO2020222315A1 (ko) * 2019-04-29 2020-11-05 주식회사 바이오셀트란 피부 또는 세포 투과능이 우수한 피부 주름 개선 또는 치료용 조성물
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
KR102192192B1 (ko) * 2019-12-06 2020-12-17 주식회사 칸젠 보툴리눔 독소 및 세포 투과성 펩타이드를 포함하는 재조합 단백질과 이를 포함하는 화장료 조성물
KR102192191B1 (ko) * 2019-12-06 2020-12-17 주식회사 칸젠 신규한 세포 투과성 펩타이드 및 이의 용도
KR102449119B1 (ko) * 2019-12-17 2022-09-30 휴젤(주) 보툴리눔 독소 유래 펩타이드 단편, 및 이를 포함하는 피부 주름 개선용 화장료 조성물
KR102469721B1 (ko) * 2020-06-12 2022-11-23 (주)케어젠 보툴리눔 톡신 유사 활성을 갖는 펩타이드 및 이의 용도
US12023400B2 (en) 2020-08-07 2024-07-02 Kan Zen Co., Ltd Recombinant proteins comprising botulinum toxin and cell penetrating peptide and cosmetic composition comprising thereof
KR102274877B1 (ko) * 2020-12-24 2021-07-08 주식회사 아임뉴런바이오사이언스 신규한 세포 투과성 펩타이드 및 이의 용도
KR102274876B1 (ko) * 2020-12-24 2021-07-08 주식회사 아임뉴런바이오사이언스 신규한 세포 투과성 펩타이드 및 이의 용도
US20240216487A1 (en) * 2021-04-26 2024-07-04 Shanghaitech University Intramuscular compositions of botulinum neurotoxins
WO2023068485A1 (ko) * 2021-10-22 2023-04-27 비피메드(주) 보툴리눔 유래 펩타이드를 포함하는 탈모개선용 조성물
KR20230057931A (ko) 2021-10-22 2023-05-02 비피메드(주) 보툴리눔 유래 펩타이드를 포함하는 탈모개선용 조성물
KR20230059121A (ko) 2021-10-25 2023-05-03 비피메드(주) 보툴리눔 유래 펩타이드를 포함하는 통증개선용 조성물
WO2023075060A1 (ko) * 2021-10-25 2023-05-04 비피메드(주) 보툴리눔 유래 펩타이드를 포함하는 통증개선용 조성물
US20240279289A1 (en) * 2023-02-17 2024-08-22 Phyto42 Methods of recombinant production of lectins
KR102666595B1 (ko) * 2023-06-16 2024-05-16 ㈜에스에이치랩 박테리오파지 유래 펩타이드를 포함하는 피부 주름 개선용 생분해성 고분자 필러 및 이의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7166692B2 (en) * 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
WO2005030119A2 (en) * 2003-04-11 2005-04-07 Allergan, Inc. Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
KR100612673B1 (ko) * 2004-08-20 2006-08-14 (주)바이오버드 세포도입성 보톡신 융합단백질
AU2006315117A1 (en) * 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US8273865B2 (en) * 2006-03-15 2012-09-25 Allergan, Inc. Multivalent clostridial toxins
CN101616928B (zh) 2007-01-29 2015-04-15 株式会社普罗赛尔制药 新型大分子转导域及其识别方法和用途
KR101258279B1 (ko) 2011-11-23 2013-04-25 주식회사 프로셀제약 세포 투과능을 개선한 개량형 신규 거대 분자 전달 도메인 개발 및 이의 이용방법
CN104039811B (zh) * 2011-11-23 2018-02-23 株式会社普罗赛尔制药 具有改善的细胞渗透性的新的大分子转导结构域的研发及其使用方法
ES2759478T3 (es) * 2012-03-12 2020-05-11 William J Binder Tratamiento de las cefaleas por migraña con neurotoxina presináptica
US20130236446A1 (en) * 2012-03-12 2013-09-12 William J. Binder Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the mouth
BR112015003591B1 (pt) * 2012-11-21 2022-02-01 Ipsen Bioinnovation Limited Usos de lys-c e métodos para fabricação de um polipeptídeo proteoliticamente processado
WO2015183044A1 (ko) * 2014-05-29 2015-12-03 주식회사 프로셀테라퓨틱스 신규한 세포투과성 펩타이드 및 이와 보툴리눔 독소 결합체 및 이들의 용도

Also Published As

Publication number Publication date
CN106459155B (zh) 2019-10-25
EP3156412A4 (en) 2017-11-29
KR101882461B1 (ko) 2018-07-27
WO2015183044A1 (ko) 2015-12-03
BR112016027773B1 (pt) 2023-12-26
CA2949653A1 (en) 2015-12-03
US10300118B2 (en) 2019-05-28
EP3156412B1 (en) 2020-01-08
CN106459155A (zh) 2017-02-22
RU2670135C2 (ru) 2018-10-18
RU2016146659A (ru) 2018-05-29
JP6243577B2 (ja) 2017-12-06
JP2017527300A (ja) 2017-09-21
KR20170002475A (ko) 2017-01-06
EP3156412A1 (en) 2017-04-19
US20170246266A1 (en) 2017-08-31
RU2016146659A3 (pt) 2018-05-29
CA2949653C (en) 2019-12-17

Similar Documents

Publication Publication Date Title
BR112016027773A2 (pt) peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
BR112018012707A2 (pt) inibidores da interação de menin-mll
BR112017018954A2 (pt) uso de forma mutante de proteína ras e método para tratar câncer
BR112018003984A2 (pt) anticorpos
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
BR112018008676A2 (pt) proteínas de fusão de fgf21 de ação prolongada e composição farmacêutica compreendendo as mesmas
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
AR088044A1 (es) Proteinas de fusion para tratar trastornos metabolicos
ECSP10010372A (es) Métodos y composiciones que utilizan polipéptidos de fusión de klotho-fgf
BR112015019064A2 (pt) métodos de tratamento de melanoma
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
EA202090683A2 (ru) Способы и композиции для лечения рака
CL2015002835A1 (es) Nuevos derivados de piridina
BR112019006853A2 (pt) composição farmacêutica líquida
BR112019024566A2 (pt) inibidores de pirazol magl
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
BR112014031841A2 (pt) formulação farmacêutica
BR112018002530A2 (pt) combinações e usos e tratamentos destas
BR112016015678B1 (pt) Polipeptídeo compreendendo um fragmento de ospa de c-terminal híbrido, seu processo de produção, seu uso, ácido nucleico, vetor, célula hospedeira, composição farmacêutica
BR112018012749A2 (pt) composições para higiene pessoal

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 7/08 (2006.01), C07K 19/00 (2006.01), A61K 39

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/05/2015, OBSERVADAS AS CONDICOES LEGAIS